KCM Capital Inc Invests $1.81 Million in Carlsmed, Inc. $CARL

KCM Capital Inc purchased a new stake in shares of Carlsmed, Inc. (NASDAQ:CARL) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 200,000 shares of the company’s stock, valued at approximately $1,810,000. Carlsmed makes up about 0.3% of KCM Capital Inc’s investment portfolio, making the stock its 28th biggest position.

A number of other hedge funds have also modified their holdings of the company. BNP Paribas Financial Markets purchased a new position in shares of Carlsmed during the 3rd quarter valued at $33,000. JPMorgan Chase & Co. purchased a new stake in Carlsmed in the 3rd quarter worth $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Carlsmed in the 3rd quarter worth $42,000. Rhumbline Advisers bought a new stake in Carlsmed during the third quarter valued at about $79,000. Finally, Wells Fargo & Company MN lifted its position in shares of Carlsmed by 61.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,834 shares of the company’s stock valued at $97,000 after acquiring an additional 2,989 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms recently commented on CARL. Needham & Company LLC began coverage on Carlsmed in a report on Wednesday, July 1st. They issued a “buy” rating and a $17.00 price target on the stock. The Goldman Sachs Group cut their price objective on shares of Carlsmed from $19.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Wall Street Zen downgraded shares of Carlsmed from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. BTIG Research restated a “buy” rating and set a $23.00 target price on shares of Carlsmed in a research report on Wednesday, May 6th. Finally, Truist Financial cut their target price on shares of Carlsmed from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $18.75.

Carlsmed Price Performance

NASDAQ:CARL opened at $11.02 on Thursday. The business’s 50-day moving average is $11.29 and its 200 day moving average is $11.35. Carlsmed, Inc. has a 12 month low of $8.50 and a 12 month high of $17.19. The company has a market capitalization of $299.52 million and a P/E ratio of -4.39. The company has a current ratio of 11.88, a quick ratio of 11.67 and a debt-to-equity ratio of 0.17.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. Carlsmed had a negative return on equity of 60.74% and a negative net margin of 57.76%.The business had revenue of $16.12 million during the quarter. On average, equities research analysts forecast that Carlsmed, Inc. will post -1.35 earnings per share for the current fiscal year.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).